Last reviewed · How we verify
Consolidation with Brentuximab Vedotin
Consolidation with Brentuximab Vedotin is a CD30-targeting antibody-drug conjugate Small molecule drug developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. It is currently in Phase 2 development for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma. Also known as: Adcetris treatment as consolidation.
Antibody-drug conjugate targeting CD30
Antibody-drug conjugate targeting CD30 Used for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.
At a glance
| Generic name | Consolidation with Brentuximab Vedotin |
|---|---|
| Also known as | Adcetris treatment as consolidation |
| Sponsor | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
| Drug class | CD30-targeting antibody-drug conjugate |
| Target | CD30 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Brentuximab vedotin is a monoclonal antibody conjugated to the microtubule inhibitor vedotin, which targets CD30-positive cells.
Approved indications
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
Common side effects
- Peripheral neuropathy
- Fatigue
- Nausea
Key clinical trials
- Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (PHASE2)
- Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (PHASE1)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (PHASE2)
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL (PHASE2)
- Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma (PHASE2)
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE2)
- A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
- Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Consolidation with Brentuximab Vedotin CI brief — competitive landscape report
- Consolidation with Brentuximab Vedotin updates RSS · CI watch RSS
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI
Frequently asked questions about Consolidation with Brentuximab Vedotin
What is Consolidation with Brentuximab Vedotin?
Consolidation with Brentuximab Vedotin is a CD30-targeting antibody-drug conjugate drug developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, indicated for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.
How does Consolidation with Brentuximab Vedotin work?
Antibody-drug conjugate targeting CD30
What is Consolidation with Brentuximab Vedotin used for?
Consolidation with Brentuximab Vedotin is indicated for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.
Who makes Consolidation with Brentuximab Vedotin?
Consolidation with Brentuximab Vedotin is developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (see full Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea pipeline at /company/grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea).
Is Consolidation with Brentuximab Vedotin also known as anything else?
Consolidation with Brentuximab Vedotin is also known as Adcetris treatment as consolidation.
What drug class is Consolidation with Brentuximab Vedotin in?
Consolidation with Brentuximab Vedotin belongs to the CD30-targeting antibody-drug conjugate class. See all CD30-targeting antibody-drug conjugate drugs at /class/cd30-targeting-antibody-drug-conjugate.
What development phase is Consolidation with Brentuximab Vedotin in?
Consolidation with Brentuximab Vedotin is in Phase 2.
What are the side effects of Consolidation with Brentuximab Vedotin?
Common side effects of Consolidation with Brentuximab Vedotin include Peripheral neuropathy, Fatigue, Nausea.
What does Consolidation with Brentuximab Vedotin target?
Consolidation with Brentuximab Vedotin targets CD30 and is a CD30-targeting antibody-drug conjugate.
Related
- Drug class: All CD30-targeting antibody-drug conjugate drugs
- Target: All drugs targeting CD30
- Manufacturer: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hodgkin lymphoma
- Indication: Drugs for Systemic anaplastic large cell lymphoma
- Also known as: Adcetris treatment as consolidation
- Compare: Consolidation with Brentuximab Vedotin vs similar drugs
- Pricing: Consolidation with Brentuximab Vedotin cost, discount & access